Venture Capital Firm I Home
Innovation.
Clarity.
Execution.
A Venture Capital Firm for Visionary Innovators.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About
As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.
We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team
Innovation.
We are backing exceptional innovation early.
Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.
As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.
Portfolio
Latest Press Releases
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
Press Release. Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 BOSTON and LONDON, April 22, 2024 (GLOBE…
Read More
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Press Release. AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations • AVB-101 is an investigational gene therapy designed to deliver…
Read More
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Press Release. Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the…
Read More
